ArticleEuropean archives of psychiatry and clinical neuroscience2026
Immunophenotype-mediated effects of plasma proteins on major depressive disorder: A two-step Mendelian randomization study.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FGF13 alleviates astrocytic apoptosis via JIP2 inhibition in the hippocampus and mitigates depression-like behavior.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The aim of this study was to investigate the mediating role of immune cells in the relationship between plasma proteins and the risk of major depressive disorder (MDD). Using a two-step, two-sample Mendelian randomization (MR) approach, we systematically assessed whether immune cells mediate the causal effects of plasma proteins on MDD. We found that eleven plasma proteins (TRABD, CACNB4, EDA, SAR1A, GLRX, COTL1, STOM, CRP, FGF22, and EDA2R) were positively associated with MDD risk, while one protein (SPTLC1) exhibited a negative association. Additionally, seven immune cell phenotypes-including CD14 on CD33dim HLA DR + CD11b + , memory B cells (% of B cells), IgD⁻ CD24⁻ % B cells, CD20 on B cells, CD27 on IgD⁺ CD24⁺, CD27 on IgD⁻ CD38dim, and CD62L on CD62L⁺ DCs-showed potential causal effects on MDD. Further mediation analysis revealed that three immune cell types mediated the effects of four plasma proteins on MDD: CD27 on IgD⁺ CD24⁺ cells mediated the effects of both COTL1 and RNF122 (mediation proportions: 5.13% and 4.50%, respectively); IgD⁻ CD24⁻ % B cells mediated the effect of EDA (12.1%); and CD62L on CD62L⁺ DCs mediated the effect of GLRX (-9.46%). The negative mediation proportion suggests a protective pathway. Sensitivity analyses supported the robustness of these findings.These results provide novel insights into immune-mediated mechanisms linking plasma proteins to MDD and may inform future research into targeted immunotherapeutic strategies.
Indexed as
Identifiers
41231246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.